VEGFA and glioblastoma: Notoriously high VEGF-A expression in GBM raised high hopes for anti-angiogenic therapy (AAT), however treatment of recurrent GBM by combination of chemoradiation and the monoclonal, humanized VEGF-A binding antibody bevacizumab (BVZ) failed to prolong overall survival6–8.